Gene: Snx25 (sorting nexin 25) Rattus norvegicus
Analyze
Symbol:
Snx25
Name:
sorting nexin 25
Description:
Predicted to have type I transforming growth factor beta receptor binding activity. Predicted to be involved in negative regulation of pathway-restricted SMAD protein phosphorylation; negative regulation of transforming growth factor beta receptor signaling pathway; and receptor catabolic process. Predicted to localize to the endosome and intracellular membrane-bounded organelle. Orthologous to human SNX25 (sorting nexin 25); INTERACTS WITH (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; 2,3,7,8-tetrachlorodibenzodioxine; 2,4-dinitrotoluene.
Type:
protein-coding
RefSeq Status:
MODEL
Also known as:
LOC306471; sorting nexin-25
Orthologs:
Species
Gene symbol and name
Data Source
Assertion derived from
less info ...
Orthologs 1
Homo sapiens (human):
SNX25 (sorting nexin 25) HGNC
EggNOG, Ensembl, HomoloGene, Inparanoid, NCBI, OMA, OrthoDB, OrthoMCL, Panther, Treefam
Mus musculus (house mouse):
Snx25 (sorting nexin 25) HGNC
Treefam, EggNOG, OrthoMCL, NCBI, OMA, HomoloGene, Inparanoid, Panther, OrthoDB, Ensembl
Chinchilla lanigera (long-tailed chinchilla):
Snx25 (sorting nexin 25) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Pan paniscus (bonobo/pygmy chimpanzee):
SNX25 (sorting nexin 25) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Canis lupus familiaris (dog):
SNX25 (sorting nexin 25) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Ictidomys tridecemlineatus (thirteen-lined ground squirrel):
Snx25 (sorting nexin 25) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Sus scrofa (pig):
SNX25 (sorting nexin 25) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Alliance orthologs 3
Homo sapiens (human):
SNX25 (sorting nexin 25)
Alliance
DIOPT (Ensembl Compara, HGNC, InParanoid, OMA, OrthoFinder, OrthoInspector, PANTHER, TreeFam)
Mus musculus (house mouse):
Snx25 (sorting nexin 25)
Alliance
DIOPT (Ensembl Compara, InParanoid, OMA, OrthoFinder, OrthoInspector, PANTHER, TreeFam)
Danio rerio (zebrafish):
snx25 (sorting nexin 25)
Alliance
DIOPT (Ensembl Compara, OMA, OrthoFinder, PANTHER, TreeFam)
Drosophila melanogaster (fruit fly):
snz
Alliance
DIOPT (Ensembl Compara, InParanoid, OMA, OrthoFinder, OrthoInspector, PANTHER, TreeFam)
Allele / Splice:
Snx25Tn(sb-T2/Bart3)2.270Mcwi
Genetic Models:
F344-Snx25Tn(sb-T2/Bart3)2.270Mcwi
Latest Assembly:
Rnor_6.0 - RGSC Genome Assembly v6.0
Position:
Rat Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl Rnor_6.0 16 49,328,958 - 49,432,415 (+) NCBI Rnor6.0 Rnor_6.0 rn6 Rnor6.0 Rnor_6.0 Ensembl 16 49,350,884 - 49,432,118 (+) Ensembl Rnor_5.0 16 49,051,539 - 49,159,381 (+) NCBI Rnor5.0 Rnor_5.0 rn5 Rnor5.0 RGSC_v3.4 16 49,415,658 - 49,518,663 (+) NCBI RGSC3.4 rn4 RGSC3.4 RGSC_v3.1 16 49,415,438 - 49,518,714 (+) NCBI Celera 16 44,133,781 - 44,236,984 (+) NCBI Celera Cytogenetic Map 16 q11 NCBI
JBrowse:
View Region in Genome Browser (JBrowse)
Model
Gene-Chemical Interaction Annotations
(-)-epigallocatechin 3-gallate multiple interactions ISO RGD:1320883 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNX25 mRNA CTD PMID:22079256 (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of SNX25 mRNA CTD PMID:25729387 17beta-hydroxy-5alpha-androstan-3-one increases expression ISO RGD:1320883 6480464 Dihydrotestosterone results in increased expression of SNX25 mRNA CTD PMID:29581250 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of SNX25 mRNA CTD PMID:21215274 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1618257 6480464 Tetrachlorodibenzodioxin affects the expression of SNX25 mRNA CTD PMID:21570461 2,4-dinitrotoluene affects expression EXP 6480464 2, 4-dinitrotoluene affects the expression of SNX25 mRNA CTD PMID:21346803 aflatoxin B2 decreases methylation ISO RGD:1320883 6480464 aflatoxin B2 results in decreased methylation of SNX25 intron CTD PMID:30157460 benzo[a]pyrene decreases expression ISO RGD:1320883 6480464 Benzo(a)pyrene results in decreased expression of SNX25 mRNA CTD PMID:20064835 benzo[a]pyrene increases expression ISO RGD:1618257 6480464 Benzo(a)pyrene results in increased expression of SNX25 mRNA CTD PMID:22228805 benzo[a]pyrene diol epoxide I decreases expression ISO RGD:1320883 6480464 7 more ... CTD PMID:19150397 benzo[e]pyrene decreases methylation ISO RGD:1320883 6480464 benzo(e)pyrene results in decreased methylation of SNX25 intron CTD PMID:30157460 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of SNX25 mRNA CTD PMID:25181051 cadmium atom increases expression ISO RGD:1320883 6480464 Cadmium results in increased expression of SNX25 mRNA CTD PMID:23369406 calcitriol multiple interactions ISO RGD:1320883 6480464 [Testosterone co-treated with Calcitriol] results in increased expression of SNX25 mRNA CTD PMID:21592394 calcitriol increases expression ISO RGD:1320883 6480464 Calcitriol results in increased expression of SNX25 mRNA CTD PMID:21592394 carbon nanotube decreases expression ISO RGD:1618257 6480464 Nanotubes, Carbon analog results in decreased expression of SNX25 mRNA, Nanotubes, Carbon results in decreased expression of SNX25 mRNA CTD PMID:25554681 chromium(6+) affects expression ISO RGD:1618257 6480464 chromium hexavalent ion affects the expression of SNX25 mRNA CTD PMID:28472532 copper(II) sulfate increases expression ISO RGD:1320883 6480464 Copper Sulfate results in increased expression of SNX25 mRNA CTD PMID:19549813 coumestrol decreases expression ISO RGD:1320883 6480464 Coumestrol results in decreased expression of SNX25 mRNA CTD PMID:19167446 dicrotophos decreases expression ISO RGD:1320883 6480464 dicrotophos results in decreased expression of SNX25 mRNA CTD PMID:28302478 dorsomorphin multiple interactions ISO RGD:1320883 6480464 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 doxorubicin decreases expression ISO RGD:1320883 6480464 Doxorubicin results in decreased expression of SNX25 mRNA CTD PMID:29803840 ethyl methanesulfonate decreases expression ISO RGD:1320883 6480464 Ethyl Methanesulfonate results in decreased expression of SNX25 mRNA CTD PMID:23649840 flutamide decreases expression EXP 6480464 Flutamide results in decreased expression of SNX25 mRNA CTD PMID:24793618 formaldehyde decreases expression ISO RGD:1320883 6480464 Formaldehyde results in decreased expression of SNX25 mRNA CTD PMID:23649840 gentamycin increases expression EXP 6480464 Gentamicins results in increased expression of SNX25 mRNA CTD PMID:22061828 hydrogen peroxide affects expression ISO RGD:1320883 6480464 Hydrogen Peroxide affects the expression of SNX25 mRNA CTD PMID:20044591 methapyrilene decreases methylation ISO RGD:1320883 6480464 Methapyrilene results in decreased methylation of SNX25 intron CTD PMID:30157460 methotrexate increases expression ISO RGD:1320883 6480464 Methotrexate results in increased expression of SNX25 mRNA CTD PMID:24449571 methyl methanesulfonate decreases expression ISO RGD:1320883 6480464 Methyl Methanesulfonate results in decreased expression of SNX25 mRNA CTD PMID:23649840 methylmercury chloride decreases expression ISO RGD:1320883 6480464 methylmercuric chloride results in decreased expression of SNX25 mRNA CTD PMID:28001369 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of SNX25 mRNA CTD PMID:25729387 panobinostat multiple interactions ISO RGD:1320883 6480464 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNX25 mRNA CTD PMID:27188386 panobinostat decreases expression ISO RGD:1320883 6480464 panobinostat results in decreased expression of SNX25 mRNA CTD PMID:26272509 potassium chromate decreases expression ISO RGD:1320883 6480464 potassium chromate(VI) results in decreased expression of SNX25 mRNA CTD PMID:22079256 potassium chromate multiple interactions ISO RGD:1320883 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNX25 mRNA CTD PMID:22079256 SB 431542 multiple interactions ISO RGD:1320883 6480464 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 sulforaphane decreases expression ISO RGD:1618257 6480464 sulforafan results in decreased expression of SNX25 mRNA CTD PMID:30529165 sulindac increases expression ISO RGD:1320883 6480464 Sulindac results in increased expression of SNX25 mRNA CTD PMID:11906190 testosterone multiple interactions ISO RGD:1320883 6480464 [Testosterone co-treated with Calcitriol] results in increased expression of SNX25 mRNA CTD PMID:21592394 testosterone increases expression ISO RGD:1320883 6480464 Testosterone results in increased expression of SNX25 mRNA CTD PMID:21592394 tetrachloromethane decreases expression EXP 6480464 Carbon Tetrachloride results in decreased expression of SNX25 mRNA CTD PMID:31150632 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of SNX25 mRNA CTD PMID:25729387 trichostatin A decreases expression ISO RGD:1320883 6480464 trichostatin A results in decreased expression of SNX25 mRNA CTD PMID:24935251 , PMID:26272509 trichostatin A affects expression ISO RGD:1320883 6480464 trichostatin A affects the expression of SNX25 mRNA CTD PMID:28542535 trichostatin A multiple interactions ISO RGD:1320883 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNX25 mRNA CTD PMID:27188386 urethane increases expression ISO RGD:1320883 6480464 Urethane results in increased expression of SNX25 mRNA CTD PMID:28818685 valproic acid increases methylation ISO RGD:1320883 6480464 Valproic Acid results in increased methylation of SNX25 gene CTD PMID:29154799 valproic acid decreases expression ISO RGD:1320883 6480464 Valproic Acid results in decreased expression of SNX25 mRNA CTD PMID:23179753 more ... valproic acid multiple interactions ISO RGD:1320883 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNX25 mRNA CTD PMID:27188386 vincristine decreases expression ISO RGD:1320883 6480464 Vincristine results in decreased expression of SNX25 mRNA CTD PMID:23649840 vorinostat multiple interactions ISO RGD:1320883 6480464 [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNX25 mRNA CTD PMID:27188386 vorinostat decreases expression ISO RGD:1320883 6480464 vorinostat results in decreased expression of SNX25 mRNA CTD PMID:26272509
Gene Ontology Annotations
Biological Process biological_process ND 1598407 12/2009: no relevant rat data RGD negative regulation of pathway-restricted SMAD protein phosphorylation ISO RGD:1320883 1624291 (PMID:21266196) RGD PMID:21266196 negative regulation of pathway-restricted SMAD protein phosphorylation IEA UniProtKB:Q9H3E2 , ensembl:ENSP000004262551600115 GO_REF:0000107 Ensembl GO_REF:0000107 negative regulation of transforming growth factor beta receptor signaling pathway ISO RGD:1320883 1624291 (PMID:21266196) RGD PMID:21266196 negative regulation of transforming growth factor beta receptor signaling pathway IEA UniProtKB:Q9H3E2 , ensembl:ENSP000004262551600115 GO_REF:0000107 Ensembl GO_REF:0000107 negative regulation of transforming growth factor beta receptor signaling pathway IEA UniProtKB:Q3ZT31 , ensembl:ENSMUSP000000357851600115 GO_REF:0000107 Ensembl GO_REF:0000107 negative regulation of transforming growth factor beta receptor signaling pathway ISO RGD:1618257 1624291 (MGI:MGI:5545984, PMID:21266196) RGD MGI:MGI:5545984 , PMID:21266196 receptor catabolic process ISO RGD:1320883 1624291 (PMID:21266196) RGD PMID:21266196 receptor catabolic process IEA UniProtKB:Q9H3E2 , ensembl:ENSP000004262551600115 GO_REF:0000107 Ensembl GO_REF:0000107 receptor catabolic process IEA UniProtKB:Q3ZT31 , ensembl:ENSMUSP000000357851600115 GO_REF:0000107 Ensembl GO_REF:0000107 receptor catabolic process ISO RGD:1618257 1624291 (MGI:MGI:5545984, PMID:21266196) RGD MGI:MGI:5545984 , PMID:21266196 Cellular Component cellular_component ND 1598407 12/2009: no relevant rat data RGD endosome ISO RGD:1618257 1624291 (MGI:MGI:5545984, PMID:21266196) RGD MGI:MGI:5545984 , PMID:21266196 endosome IEA UniProtKB:Q3ZT31 , ensembl:ENSMUSP000000357851600115 GO_REF:0000107 Ensembl GO_REF:0000107 intracellular membrane-bounded organelle IEA UniProtKB:Q9H3E2 , ensembl:ENSP000004262551600115 GO_REF:0000107 Ensembl GO_REF:0000107 intracellular membrane-bounded organelle ISO RGD:1320883 1624291 RGD GO_REF:0000052 Molecular Function molecular_function ND 1598407 12/2009: no relevant rat data RGD phosphatidylinositol binding IEA InterPro:IPR001683 , InterPro:IPR036871 1600115 GO_REF:0000002 InterPro GO_REF:0000002 type I transforming growth factor beta receptor binding ISO RGD:1618257 1624291 UniProtKB:Q64729 (MGI:MGI:5545984 , PMID:21266196) RGD MGI:MGI:5545984 , PMID:21266196 type I transforming growth factor beta receptor binding IEA UniProtKB:Q3ZT31 , ensembl:ENSMUSP000000357851600115 GO_REF:0000107 Ensembl GO_REF:0000107
1600378 Arunc4 Aerobic running capacity QTL 4 0.03 exercise endurance trait (VT:0002332) maximum distance run on treadmill (CMO:0001406) 16 1090054 86162972 Rat 2312660 Bw95 Body weight QTL 95 0.05 inguinal fat pad mass (VT:0010424) inguinal fat pad weight to body weight ratio (CMO:0001253) 16 1550187 63210301 Rat 2312663 Slep9 Serum leptin concentration QTL 9 0.001 blood leptin amount (VT:0005667) serum leptin level (CMO:0000780) 16 1550187 63210301 Rat 2312666 Insul16 Insulin level QTL 16 0.01 blood insulin amount (VT:0001560) serum insulin level (CMO:0000358) 16 1550187 63210301 Rat 2312669 Stl23 Serum triglyceride level QTL 23 0.01 blood triglyceride amount (VT:0002644) serum triglyceride level (CMO:0000360) 16 1550187 63210301 Rat 61338 Bp23 Blood pressure QTL 23 4.3 arterial blood pressure trait (VT:2000000) systolic blood pressure (CMO:0000004) 16 5013802 50013802 Rat 737819 Hcas4 Hepatocarcinoma susceptibility QTL 4 4.43 liver integrity trait (VT:0010547) volume of individual liver tumorous lesion (CMO:0001078) 16 5013802 50169318 Rat 61405 Niddm6 Non-insulin dependent diabetes mellitus QTL 6 3.66 0.001 blood glucose amount (VT:0000188) plasma glucose level (CMO:0000042) 16 5013802 52144919 Rat 737826 Alc11 Alcohol consumption QTL 11 3.2 consumption behavior trait (VT:0002069) ethanol drink intake rate (CMO:0001407) 16 5013802 64012784 Rat 70205 Gcr3 Gastric cancer resistance QTL 3 2.3 stomach morphology trait (VT:0000470) stomach tumor depth of invasion (CMO:0001888) 16 19398187 70590230 Rat 70205 Gcr3 Gastric cancer resistance QTL 3 2.3 stomach morphology trait (VT:0000470) stomach tumor diameter (CMO:0001889) 16 19398187 70590230 Rat 70205 Gcr3 Gastric cancer resistance QTL 3 2.3 stomach morphology trait (VT:0000470) stomach tumor depth of invasion (CMO:0001888) 16 19398187 70590230 Rat 70205 Gcr3 Gastric cancer resistance QTL 3 2.3 stomach morphology trait (VT:0000470) stomach tumor diameter (CMO:0001889) 16 19398187 70590230 Rat 70215 Niddm29 Non-insulin dependent diabetes mellitus QTL 29 3.54 blood glucose amount (VT:0000188) blood glucose level area under curve (AUC) (CMO:0000350) 16 20755556 80316424 Rat 2302057 Pia29 Pristane induced arthritis QTL 29 3.6 0.001 blood autoantibody amount (VT:0003725) serum immunoglobulin M-type rheumatoid factor level relative to an arbitrary reference serum (CMO:0002111) 16 24846541 69846541 Rat 8694453 Bw172 Body weight QTL 172 8.33 0.001 retroperitoneal fat pad mass (VT:0010430) retroperitoneal fat pad weight to body weight ratio (CMO:0000635) 16 27519980 72519980 Rat 6903294 Stl30 Serum triglyceride level QTL 30 2.6 0.0013 blood triglyceride amount (VT:0002644) plasma triglyceride level (CMO:0000548) 16 28340315 73340315 Rat 1298529 Arunc1 Aerobic running capacity QTL 1 4 exercise endurance trait (VT:0002332) maximum distance run on treadmill (CMO:0001406) 16 35307110 63909364 Rat 1578768 Stresp22 Stress response QTL 22 2.8 thymus mass (VT:0004954) thymus wet weight (CMO:0000855) 16 39000021 84000021 Rat 2300163 Bmd64 Bone mineral density QTL 64 5.3 0.0001 lumbar vertebra mineral mass (VT:0010511) volumetric bone mineral density (CMO:0001553) 16 41512710 86512710 Rat 2293690 Bss45 Bone structure and strength QTL 45 5.13 0.0001 lumbar vertebra morphology trait (VT:0010494) lumbar vertebra cortical cross-sectional area (CMO:0001690) 16 41512710 86512710 Rat 631833 Sach2 Saccharin preference QTL 2 4 0.01 consumption behavior trait (VT:0002069) calculated saccharin drink intake rate (CMO:0001613) 16 45905097 53253355 Rat 7205510 Activ5 Activity QTL 5 3.78 0.00028 locomotor behavior trait (VT:0001392) number of entries into a discrete space in an experimental apparatus (CMO:0000960) 16 46558188 90668790 Rat
This gene
Snx25 is modified in the following models/strains
Predicted Target Of
Count of predictions: 71 Count of miRNA genes: 58 Interacting mature miRNAs: 69 Transcripts: ENSRNOT00000014828 Prediction methods: Miranda, Rnahybrid, Targetscan Result types: miRGate_prediction
Gene-Chemical Interaction Annotations
